Pyxis Oncology, Inc.
PYXS
$1.14
-$0.05-4.20%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -64.75% | -4.80% | 39.17% | 40.15% | 46.76% |
| Total Depreciation and Amortization | -15.25% | 54.75% | 118.47% | 163.47% | 285.02% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 141.27% | 122.34% | -66.80% | -58.68% | -56.99% |
| Change in Net Operating Assets | 125.20% | -1.36% | -74.38% | -232.33% | -178.67% |
| Cash from Operations | 7.87% | 18.44% | 26.37% | 25.41% | 27.03% |
| Capital Expenditure | 100.00% | 96.48% | 97.24% | 97.67% | 76.01% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -99.98% | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 251.38% | 108.01% | 93.01% | 92.99% | 70.46% |
| Cash from Investing | 277.31% | 107.78% | 92.92% | 98.67% | 77.33% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -85.16% | 954.53% | 959.45% | 847.79% | 915,342.86% |
| Repurchase of Common Stock | -1,100.62% | -1,673.03% | 25.70% | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -97.14% | 900.61% | 895.15% | 836.63% | 906,185.71% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 39.39% | 105.78% | 98.55% | 99.58% | 87.08% |